HHS Proposes Enforcement Discretion for Peptide 503A Compounding
HHS published a draft Federal Register notice on October 30, 2026 announcing interim enforcement discretion for 503A compounding using certain peptide bulk drug substances.
On October 30, 2026, the Secretary of Health and Human Services published a notice of availability in the Federal Register (FR Doc. 2026-22192; RIN 0910-ZD94) announcing a draft Enforcement Discretion Policy on 503A compounding using certain peptide bulk drug substances. The material reviewed here is a law-firm analysis of that notice rather than the full text, so the specific peptides covered, the boundaries of the discretion, and the comment deadline could not be confirmed.
The development matters because Section 503A governs when pharmacies may compound without an approved application, and whether a given bulk substance may be used as an input has been a recurring source of enforcement exposure for compounding pharmacies and telehealth platforms. A stated enforcement posture changes the risk calculus for compounders, for prescribers, distributors and telehealth operators, and for manufacturers of peptide products who compete with compounded versions. Counsel should read the actual notice and any companion guidance before advising clients on sourcing, compounding, or promotional claims.
The concrete next step to watch is the close of the comment period and the final policy's text, together with any FDA inspection, import or warning-letter activity that follows in the interim.